235 related articles for article (PubMed ID: 15711258)
1. Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE.
Kane CJ; Bassett WW; Sadetsky N; Silva S; Wallace K; Pasta DJ; Cooperberg MR; Chan JM; Carroll PR
J Urol; 2005 Mar; 173(3):732-6. PubMed ID: 15711258
[TBL] [Abstract][Full Text] [Related]
2. Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE.
Bassett WW; Cooperberg MR; Sadetsky N; Silva S; DuChane J; Pasta DJ; Chan JM; Anast JW; Carroll PR; Kane CJ
Urology; 2005 Nov; 66(5):1060-5. PubMed ID: 16286124
[TBL] [Abstract][Full Text] [Related]
3. Prostate brachytherapy: a descriptive analysis from CaPSURE.
Lee WR; Sharkey J; Cowan JE; DuChane J; Carroll PR;
Brachytherapy; 2007; 6(2):123-8. PubMed ID: 17434105
[TBL] [Abstract][Full Text] [Related]
4. The prevalence of erectile dysfunction among Brazilian men screened for prostate cancer.
Paranhos M; Antunes A; Andrade E; Freire G; Srougi M
BJU Int; 2009 Oct; 104(8):1130-3. PubMed ID: 19426190
[TBL] [Abstract][Full Text] [Related]
5. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
Culp S; Porter M
BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
[TBL] [Abstract][Full Text] [Related]
6. The impact of obesity on overall and cancer specific survival in men with prostate cancer.
Davies BJ; Smaldone MC; Sadetsky N; Dall'era M; Carroll PR
J Urol; 2009 Jul; 182(1):112-7; discussion 117. PubMed ID: 19447437
[TBL] [Abstract][Full Text] [Related]
7. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE.
Mitchell JA; Cooperberg MR; Elkin EP; Lubeck DP; Mehta SS; Kane CJ; Carroll PR
J Urol; 2005 Apr; 173(4):1126-31. PubMed ID: 15758720
[TBL] [Abstract][Full Text] [Related]
8. Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer.
Palma D; Pickles T; Tyldesley S;
BJU Int; 2007 Aug; 100(2):315-9. PubMed ID: 17617138
[TBL] [Abstract][Full Text] [Related]
9. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
[TBL] [Abstract][Full Text] [Related]
10. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial.
Gong Z; Neuhouser ML; Goodman PJ; Albanes D; Chi C; Hsing AW; Lippman SM; Platz EA; Pollak MN; Thompson IM; Kristal AR
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1977-83. PubMed ID: 17035408
[TBL] [Abstract][Full Text] [Related]
11. Body mass index as a predictor of prostate cancer: development versus detection on biopsy.
Freedland SJ; Terris MK; Platz EA; Presti JC
Urology; 2005 Jul; 66(1):108-13. PubMed ID: 15992911
[TBL] [Abstract][Full Text] [Related]
12. [Relationship between serum prostate-specific antigen levels and body mass index in Beijing men over 50 years of age].
Wang Y; Zhou Z; Tian Y; Shao Q; Chen S; Hong BF; Zhang XH; Ren XH; Sun WX; Wang ZW; Na YQ
Zhonghua Yi Xue Za Zhi; 2009 Jun; 89(24):1681-3. PubMed ID: 19957525
[TBL] [Abstract][Full Text] [Related]
13. Obesity does not increase the risk of lymph node metastases in patients with clinically localized prostate cancer undergoing radical prostatectomy and extended pelvic lymph node dissection.
Briganti A; Karakiewicz PI; Chun FK; Suardi N; Gallina A; Abdollah F; Freschi M; Doglioni C; Rigatti P; Montorsi F
Int J Urol; 2009 Aug; 16(8):676-81. PubMed ID: 19602006
[TBL] [Abstract][Full Text] [Related]
14. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM
J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life for men with prostate cancer and diabetes: a longitudinal analysis from CaPSURE.
Latini DM; Chan JM; Cowan JE; Arredondo SA; Kane CJ; Penson DF; DuChane J; Carroll PR;
Urology; 2006 Dec; 68(6):1242-7. PubMed ID: 17141841
[TBL] [Abstract][Full Text] [Related]
16. A better prognosis for obese men with prostate cancer.
Daniell HW
J Urol; 1996 Jan; 155(1):220-5. PubMed ID: 7490839
[TBL] [Abstract][Full Text] [Related]
17. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
18. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE).
Meng MV; Elkin EP; Latini DM; Duchane J; Carroll PR
J Urol; 2005 May; 173(5):1557-61. PubMed ID: 15821485
[TBL] [Abstract][Full Text] [Related]
19. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE.
Ryan CJ; Elkin EP; Small EJ; Duchane J; Carroll P
Urol Oncol; 2006; 24(5):396-402. PubMed ID: 16962488
[TBL] [Abstract][Full Text] [Related]
20. Obesity and the risk of prostate cancer (United States).
Bradbury BD; Wilk JB; Kaye JA
Cancer Causes Control; 2005 Aug; 16(6):637-41. PubMed ID: 16049801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
